Cipla expects sales of branded generics to cross $1 billion this fiscal

Cipla's branded generics business reported sales of around ₹6,000 crore in FY21. The drug maker's India business, which consists of prescription, trade generics and consumer health divisions, generated sales of ₹5,126 crore in the first half of this fiscal year, compared with ₹3,698 crore in H1FY21, an increase of 39%.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2ZHPeH2
via IFTTT